Pathogenesis and classification of eosinophil disorders

A review of recent developments in the field

Peter Valent, Gerald J. Gleich, Andreas Reiter, Florence Roufosse, Peter F. Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M. Leiferman, Michel Arock, Karl Sotlar, Joseph H. Butterfield, Sabine Cerny-Reiterer, Matthias Mayerhofer, Peter Vandenberghe, Torsten Haferlach, Bruce S. Bochner, Jason Gotlib, Hans Peter Horny, Hans Uwe Simon, Amy D. Klion

Research output: Contribution to journalArticle

Abstract

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

Original languageEnglish (US)
Pages (from-to)157-176
Number of pages20
JournalExpert Review of Hematology
Volume5
Issue number2
DOIs
StatePublished - 2012

Fingerprint

Eosinophils
Eosinophilia
Adjustment Disorders
Reducing Agents
Therapeutics
Pathology
Cytokines

Keywords

  • classification
  • eosinophilic leukemia
  • FIP1L1-PDGFRA
  • hypereosinophilia
  • hypereosinophilic syndromes
  • targeted therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., ... Klion, A. D. (2012). Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Review of Hematology, 5(2), 157-176. https://doi.org/10.1586/ehm.11.81

Pathogenesis and classification of eosinophil disorders : A review of recent developments in the field. / Valent, Peter; Gleich, Gerald J.; Reiter, Andreas; Roufosse, Florence; Weller, Peter F.; Hellmann, Andrzej; Metzgeroth, Georgia; Leiferman, Kristin M.; Arock, Michel; Sotlar, Karl; Butterfield, Joseph H.; Cerny-Reiterer, Sabine; Mayerhofer, Matthias; Vandenberghe, Peter; Haferlach, Torsten; Bochner, Bruce S.; Gotlib, Jason; Horny, Hans Peter; Simon, Hans Uwe; Klion, Amy D.

In: Expert Review of Hematology, Vol. 5, No. 2, 2012, p. 157-176.

Research output: Contribution to journalArticle

Valent, P, Gleich, GJ, Reiter, A, Roufosse, F, Weller, PF, Hellmann, A, Metzgeroth, G, Leiferman, KM, Arock, M, Sotlar, K, Butterfield, JH, Cerny-Reiterer, S, Mayerhofer, M, Vandenberghe, P, Haferlach, T, Bochner, BS, Gotlib, J, Horny, HP, Simon, HU & Klion, AD 2012, 'Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field', Expert Review of Hematology, vol. 5, no. 2, pp. 157-176. https://doi.org/10.1586/ehm.11.81
Valent, Peter ; Gleich, Gerald J. ; Reiter, Andreas ; Roufosse, Florence ; Weller, Peter F. ; Hellmann, Andrzej ; Metzgeroth, Georgia ; Leiferman, Kristin M. ; Arock, Michel ; Sotlar, Karl ; Butterfield, Joseph H. ; Cerny-Reiterer, Sabine ; Mayerhofer, Matthias ; Vandenberghe, Peter ; Haferlach, Torsten ; Bochner, Bruce S. ; Gotlib, Jason ; Horny, Hans Peter ; Simon, Hans Uwe ; Klion, Amy D. / Pathogenesis and classification of eosinophil disorders : A review of recent developments in the field. In: Expert Review of Hematology. 2012 ; Vol. 5, No. 2. pp. 157-176.
@article{c8bd8f4a12384f5a8b37771ec1fd82e3,
title = "Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field",
abstract = "Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.",
keywords = "classification, eosinophilic leukemia, FIP1L1-PDGFRA, hypereosinophilia, hypereosinophilic syndromes, targeted therapy",
author = "Peter Valent and Gleich, {Gerald J.} and Andreas Reiter and Florence Roufosse and Weller, {Peter F.} and Andrzej Hellmann and Georgia Metzgeroth and Leiferman, {Kristin M.} and Michel Arock and Karl Sotlar and Butterfield, {Joseph H.} and Sabine Cerny-Reiterer and Matthias Mayerhofer and Peter Vandenberghe and Torsten Haferlach and Bochner, {Bruce S.} and Jason Gotlib and Horny, {Hans Peter} and Simon, {Hans Uwe} and Klion, {Amy D.}",
year = "2012",
doi = "10.1586/ehm.11.81",
language = "English (US)",
volume = "5",
pages = "157--176",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Pathogenesis and classification of eosinophil disorders

T2 - A review of recent developments in the field

AU - Valent, Peter

AU - Gleich, Gerald J.

AU - Reiter, Andreas

AU - Roufosse, Florence

AU - Weller, Peter F.

AU - Hellmann, Andrzej

AU - Metzgeroth, Georgia

AU - Leiferman, Kristin M.

AU - Arock, Michel

AU - Sotlar, Karl

AU - Butterfield, Joseph H.

AU - Cerny-Reiterer, Sabine

AU - Mayerhofer, Matthias

AU - Vandenberghe, Peter

AU - Haferlach, Torsten

AU - Bochner, Bruce S.

AU - Gotlib, Jason

AU - Horny, Hans Peter

AU - Simon, Hans Uwe

AU - Klion, Amy D.

PY - 2012

Y1 - 2012

N2 - Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

AB - Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

KW - classification

KW - eosinophilic leukemia

KW - FIP1L1-PDGFRA

KW - hypereosinophilia

KW - hypereosinophilic syndromes

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84863805992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863805992&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.81

DO - 10.1586/ehm.11.81

M3 - Article

VL - 5

SP - 157

EP - 176

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -